Show simple item record

dc.contributor.authorCooney, Maeve
dc.date.accessioned2018-10-11T10:06:47Z
dc.date.available2018-10-11T10:06:47Z
dc.date.issued2018-09
dc.identifier.urihttp://hdl.handle.net/10147/623854
dc.descriptionMedication-related osteonecrosis of the jaws (MRONJ) is a potentially severe adverse drug reaction, resulting in progressive bone destruction of the jaws. MRONJ is associated with two classes of therapeutic drugs: antiresorptive and anti-angiogenic agents. There are several hypotheses that attempt to explain the aetiology of the process and its unique localisation to the jaws. Dental screening and appropriate treatment are fundamental to reduce the risk of osteonecrosis before patients begin taking these medications. The treatment of MRONJ often presents great difficulty and an optimal therapy strategy is yet to be established. For this reason, prevention occupies a pivotal role in the management of these patients.en_US
dc.language.isoenen_US
dc.publisherIrish Dental Associationen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectDENTAL HEALTHen_US
dc.titleMedication-related osteonecrosis of the jaws (MRONJ) review: what Irish dentists need to know, from international guidelines to current controversiesen_US
dc.typeArticleen_US
dc.identifier.journalIrish Dental Associationen_US
refterms.dateFOA2018-10-11T10:06:48Z


Files in this item

Thumbnail
Name:
art1Sept.pdf
Size:
230.3Kb
Format:
PDF
Description:
Main Article

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 United States
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States